Dr. Scott M. Rocklage received his B.S. in Chemistry from the University of California, Berkley and went on to receive his Ph.D. in Chemistry from the Massachusetts Institute of Technology. While studying for his doctorate, he conducted research with the Nobel Prize winner Richard R. Schrock’s laboratory. Upon completing his education, Dr. Scott Rocklage has written more than 100 peer-reviewed publications and has invented or co-invented over 30 U.S. patents with the FDA.
Dr. Rocklage has acted as a Board Member in different organizations.From 1990 to 1994 Dr. Rocklage served as President and CEO of Nycomed Salutar, Inc. In 1992, he also served as the President and CEO of Nycomed Interventional, Inc. In 1994, he became the Founding CEO of Cubist Pharmaceuticals Inc. and has held an array of different positions at Salutar and Catalytica. He became Chairman of Novira Therapeutics in August 2012 and Chairman of the Board for Cidara Therapeutics in 2013.
Dr. Rocklage joined 5AM Ventures in 2003 as a Venture Partner. The company is a venture capital firm based on life science. In 2004, he gained strategic leadership responsibility as the Managing Partner that has led to the approval of three U.S. New Drug Applications, namely Ominscan, Teslascan, and Cubicin by the FDA. His initiative has also led to six drug candidates to enter into clinical trials and learn more about Scott.
They study new areas of life science, such as the ability to target genotypes to treat cancerous cells in unique ways. He also guides portfolio company’s management team and attends Board meetings to encourage the companies to take measured risks while sticking to their strengths. Currently, he serves as Board Chairman of Achaogen, Relypsa, and Semprus. He is also on the Boards of WaveRx, Pulmatrix, and Variation. Dr. Rocklage also serves on the Whitehead Institute Board of Associates and more information click here.
With years of extensive healthcare management, strategic leadership, and with his scientific background, Dr. Rocklage has guided 5AM Ventures to establish value in early-stage life science companies and creating return realization. 5AM Ventures seeks to transcend passive board roles, encourage hands-on company building to proactively guide the company and to enhance overall individual company performance and returns.
More visit: https://ideamensch.com/scott-rocklage/